IFN-β treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis

• Published in: Multiple sclerosis 2004-12, Vol.10 (6), p.630-635
• Main Authors: Espejo, C, Brieva, L, Ruggiero, G, Río, J, Montalban, X, Martínez-Cáceres, E M
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - administration & dosage; Adult; Animals; Antigens, CD; Antigens, Differentiation - metabolism; B7-1 Antigen - pharmacology; Biological and medical sciences; CD28 Antigens - metabolism; Cell Division - drug effects; Cell Division - immunology; Cell Line, Tumor; CTLA-4 Antigen; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Female; Humans; Immunomodulators; Interferon-beta - administration & dosage; Interleukin-2 - metabolism; Male; Mastocytoma; Medical sciences; Middle Aged; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - immunology; Multiple Sclerosis, Relapsing-Remitting - metabolism; Neurology; Pharmacology. Drug treatments; T-Lymphocytes - cytology; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Up-Regulation - drug effects; Up-Regulation - immunology
• ISSN: 1352-4585; 1477-0970
• DOI: 10.1191/1352458504ms1094oa

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system probably mediated by Th1 lymphocytes. IFN-b is an established therapy for relapsing MS patients, although the mechanisms underlying its efficacy are yet to be well characterized. We determined IL-2 production, CD25 expression and T-cell proliferation from relapsing -remitting MS patients before and three months after starting therapy. A decrease in the percentage of CD80-induced IL-2-producing cells was observed after in vivo IFN-b treatment. These data support that one of the immunomodulatory effects of IFN-b treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway.